Journal of Urology ( White Journal) In Press
The Journal of Urology RSS feed.
Updated: 1 hour 10 min ago
A Prediction Model using Machine Learning Algorithm for Assessing Stone-Free Status after Single-Session Shockwave Lithotripsy to Treat Ureteral Stones
The aim of this study was to develop and validate a decision support model using machine learning algorithm to predict treatment success after single-session SWL in ureteral stone patients.
Acute Kidney Injury after Partial Nephrectomy in Solitary Kidneys: Impact on Long-term Stability of Renal Function
Acute kidney injury (AKI) often leads to chronic kidney disease (CKD) in the general population. The long-term functional impact of AKI observed after partial nephrectomy (PN) has not been adequately studied.
We assessed the outcomes of high-intensity focused ultrasound for the primary treatment of localized prostate cancer in a retrospective series. This represents one of the largest published series of intermediate and high-risk patients.
Impact of Potassium Citrate vs. Citric Acid on Urinary Stone Risk in Calcium Phosphate Stone Formers
No medication has been shown to be effective at preventing recurrence of calcium phosphate urinary stones. Potassium citrate may protect against calcium phosphate stones by enhancing urine citrate excretion and lowering urine calcium, but it raises urine pH which increases calcium phosphate saturation and may negate the beneficial effects. Citric acid can potentially raise urine citrate but not pH, and thus may be a useful countermeasure against calcium phosphate stones. We aimed to assess whether these two agents can significantly alter urine composition and reduce calcium phosphate saturation.
This post hoc analysis of the well-known dietary trial of Borghi et al (reference 15 in article) addresses a knowledge gap regarding whether urinary supersaturation indexes predict kidney stone recurrence. It is important to note that in the original study the 24-hour urine parameters dramatically improved after intervention at week 1 and the improvements were generally sustained in the following years.
Hypospadias is one of the most common conditions encountered and arguably one of the most challenging anomalies to be treated by pediatric urologists. The parental stress associated with this disorder naturally leads parents to ask 2 age-old questions: “Why did this happen?” and “Could this happen again in subsequent offspring?”
For several decades it has been appreciated that multi-agent cisplatin based chemotherapy leads to a pathological complete response in about 30% to 40% of patients with muscle invasive urothelial cancer of the bladder and such a response confers a highly favorable prognosis. Ironically proving that a pathological complete response has occurred requires surgical removal of the bladder and the potential morbidity associated with the procedure.
Muscle invasive bladder cancer is a challenging disease to treat. Balancing long-term disease control while minimizing short-term and long-term morbidity and maximizing quality of life is difficult when your tools are relatively toxic systemic chemotherapy, radiation therapy and radical cystectomy. Historically the urological community has been slow to consider alternate treatments compared to radical cystectomy as reflected in the relatively low use of neoadjuvant chemotherapy and trimodal therapy.
In the current NCDB derived study short-term and long-term outcomes after chemotherapy of MIBC were evaluated in patients who did not undergo cystectomy or radiation after bladder tumor TUR. During a 10-year period 1,538 patients underwent chemotherapy alone after TUR while 17,866 underwent undergone cystectomy with or without chemotherapy. The authors noted that patients who did not undergo cystectomy had lower 30 and 90-day mortality rates than those who underwent cystectomy. The noncystectomy group was older, less insured, more likely to be African American, less likely to receive care at an academic facility and most importantly had poorer overall survival than patients who underwent cystectomy.
Systemic chemotherapy prior to radical cystectomy has been shown to improve survival in MIBC with the best outcomes in patients who achieve a complete pathological response (pT0) (reference 8 in article). The current data from Audenet et al suggest that chemotherapy alone in select patients without cystectomy may result in up to 36% 5-year survival. The implication is that cystectomy can be safely delayed or even eliminated in some individuals with MIBC. However, these results must be interpreted with caution.
Re: Effect of Uterosacral Ligament Suspension vs Sacrospinous Ligament Fixation with or without Perioperative Behavioral Therapy for Pelvic Organ Vaginal Prolapse on Surgical Outcomes and Prolapse Symptoms at 5 Years in the OPTIMAL Randomized Clinical...
J. E. Jelovsek, M. D. Barber, L. Brubaker, P. Norton, M. Gantz, H. E. Richter, A. Weidner, S. Menefee, J. Schaffer, N. Pugh and S. Meikle; NICHD Pelvic Floor Disorders Network
A. G. Hester, A. Kretschmer and G. Badlani
D. B. Hennessey, N. Hoag and J. Gani
Re: Short-Term Complications Associated with the Use of Transvaginal Mesh in Pelvic Floor Reconstructive Surgery: Results from a Multi-Institutional Prospectively Maintained Dataset
M. Caveney, D. Haddad, C. Matthews, G. Badlani and M. Mirzazadeh
Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial
R. M. Martin, J. L. Donovan, E. L. Turner, C. Metcalfe, G. J. Young, E. I. Walsh, J. A. Lane, S. Noble, S. E. Oliver, S. Evans, J. A. C. Sterne, P. Holding, Y. Ben-Shlomo, P. Brindle, N. J. Williams, E. M. Hill, S. Y. Ng, J. Toole, M. K. Tazewell, L. J. Hughes, C. F. Davies, J. C. Thorn, E. Down, G. Davey Smith, D. E. Neal and F. C. Hamdy; CAP Trial Group
Re: Short-Term Effects of Transdermal Estradiol in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial
N. Russell, R. Hoermann, A. S. Cheung, M. Ching, J. D. Zajac, D. J. Handelsman and M. Grossmann
V. Kasivisvanathan, A. S. Rannikko, M. Borghi, V. Panebianco, L. A. Mynderse, M. H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R. G. Hindley, M. J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G. M. Villeirs, J. Virdi, S. Boxler, G. Robert, P. B. Singh, W. Venderink, B. A. Hadaschik, A. Ruffion, J. C. Hu, D. Margolis, S. Crouzet, L. Klotz, S. S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N. R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M.
L. Dell’Atti and A. B. Galosi
Re: Safety and Feasibility of Platelet Rich Fibrin Matrix Injections for Treatment of Common Urologic Conditions
E. L. Matz, A. M. Pearlman and R. P. Terlecki